Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) has announced that its controlling subsidiary, Fosun Pharma Singapore, executed a share sale of Gland Pharma shares on September 4, 2026 (Indian time). The transaction involved the disposal of a total of 9.897 million shares through block trades and continuous bidding, representing approximately 6.00% of Gland Pharma's total shares as of September 3, 2026.

The total consideration for the deal, before deducting trading commissions and taxes, reached 27.996 billion Indian rupees (roughly $294 million). The average selling price, also pre-fees, stood at approximately 2,828.78 Indian rupees per share, reflecting a discount of about 2.72% compared to the previous trading day's closing price of 2,907.90 Indian rupees. The share transfer is expected to be completed on September 7, 2026 (Indian time).

Following the completion of this transaction, the group will retain approximately 45.76% equity in Gland Pharma, down from around 51.76% prior to the sale. The company will remain the controlling shareholder, and Gland Pharma will continue to be consolidated as a subsidiary in the group's financial statements.

The proceeds from this disposal are slated primarily for research and development investments, share buybacks, and repayment of interest-bearing debt. While the sale is set to bolster the group's net assets, it will not be recorded as investment income in the profit and loss statement, given that the transaction involves the partial transfer of equity in a controlled subsidiary.